- Clinical Trials
Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.
A UPMC Children’s Hospital of Pittsburgh researcher is crediting a new, supportive environment for entrepreneurs at the University of Pittsburgh for making it possible to license a technology that may one day cure diabetes.
Genprex will present at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be answering questions from investors.
Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.
Austin-based biotech firm Genprex is looking for more growth after raising about $25.5 million through two recent stock offerings.
The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.
The closing of the registered direct offering is expected to take place on or about February 21, 2020, subject to the satisfaction of customary closing conditions.
Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.
Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh.
Genprex signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.